2. Academic Validation
  3. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold

Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold

  • Bioorg Med Chem Lett. 2014 Jan 15;24(2):462-6. doi: 10.1016/j.bmcl.2013.12.048.
Giuseppe Giannini 1,  Gianfranco Battistuzzi 2,  Loredana Vesci 2,  Ferdinando M Milazzo 2,  Francesca De Paolis 2,  Marcella Barbarino 2,  Mario Berardino Guglielmi 2,  Valeria Carollo 2,  Grazia Gallo 2,  Roberto Artali 3,  Sabrina Dallavalle 4
Affiliations

Affiliations

  • 1 R&D Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina Km 30,400, I-00040 Pomezia (RM), Italy. Electronic address: giuseppe.giannini@sigma-tau.it.
  • 2 R&D Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina Km 30,400, I-00040 Pomezia (RM), Italy.
  • 3 Scientia Advice di Roberto Artali, 20832 Desio (MB), Italy.
  • 4 Department of Food, Environmental and Nutritional Sciences, Division of Chemistry and Molecular Biology, Università di Milano, Via Celoria 2, 20133 Milano, Italy.
PMID: 24388690 DOI: 10.1016/j.bmcl.2013.12.048
Abstract

Poly(ADP-ribose)polymerase-I (PARP-1) Enzyme is involved in maintaining DNA integrity and programmed cell death. A virtual screening of commercial libraries led to the identification of five novel scaffolds with inhibitory profile in the low nanomolar range. A hit-to-lead optimization led to the identification of a group of new potent PARP-1 inhibitors, acyl-piperazinylamides of 3-(4-oxo-3,4-dihydro-quinazolin-2-yl)-propionic acid. Molecular modeling studies highlighted the preponderant role of the propanoyl side chain.

Keywords

3-(4-Oxo-3,4-dihydro-quinazolin-2-yl)-propionamides; Anticancer; Hit-to-lead optimization; Molecular modeling; PARP-1 inhibitors; Virtual screening of commercial libraries.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z